| Literature DB >> 29472775 |
Song Fu1, Renhua Lv2, Longqiang Wang1, Haitao Hou1, Haijun Liu1, Shize Shao1.
Abstract
Resveratrol, a polyphenol found in various plants, including grapes, plums and peanuts has shown various medIRInal properties, including antioxidant, protection of cardiovascular disease and cancer risk. However, the effects of resveratrol on spinal cord reperfusion injury have not been investigated. Hence, the present study was designed to evaluate the effect of resveratrol on nitric oxide synthase (iNOS)/p38MAPK signaling pathway and to elucidate its regulating effect on the protection of spinal cord injury. Spinal cord ischemia-reperfusion injury (IRI) was performed by the infrarenal abdominal aorta with mini aneurysm clip model. The expressions of iNOS and p38MAPK and the levels of biochemical parameters, including nitrite/nitrate, malondialdehyde (MDA), advanced oxidation products (AOPP), reduced glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT) were measured in control and experimental groups. IRI-induced rats treated with 10 mg/kg resveratrol protected spinal cord from ischemia injury as supported by improved biological parameters measured in spinal cord tissue homogenates. The resveratrol treatment significantly decreased the levels of plasma nitrite/nitrate, iNOS mRNA and protein expressions and phosphorylation of p38MAPK in IRI-induced rats. Further, IRI-produced free radicals were reduced by resveratrol treatment by increasing enzymatic and non-enzymatic antioxidant levels such as GSH, SOD and CAT. Taken together, administration of resveratrol protects the damage caused by spinal cord ischemia with potential mechanism of suppressing the activation of iNOS/p38MAPK pathway and subsequent reduction of oxidative stress due to IRI.Entities:
Keywords: Antioxidant; Resveratrol; Spinal cord; iNOS; p38MAPk
Year: 2016 PMID: 29472775 PMCID: PMC5815991 DOI: 10.1016/j.sjbs.2016.10.019
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 1319-562X Impact factor: 4.219
Rats were divided into five groups with seven rats in each group, as follows.
| Groups | Treatment |
|---|---|
| Group I (Con) | Control rats received 1 ml of vehicle (Saline) by intraperitoneal injection without surgery |
| Group II (Resv) | Rats received 1 ml of resveratrol (10 mg/kg body weight) by intraperitoneal injection without surgery |
| Group III (Sham) | Rats subjected to laparotomy and infrarenal abdominal aorta dissection without clamping of the aorta |
| Group IV (IRI) | Rats received 1 ml of vehicle (saline) by intraperitoneal injection following a 45-min spinal cord ischemia–reperfusion (IRI) |
| Group V (IRI + Resv) | Rats received 1 ml of resveratrol (10 mg/kg body weight) by intraperitoneal injection following a 45-min spinal cord ischemia–reperfusion |
Figure 1Effect of resveratrol on plasma nitrite/nitrate and iNOS mRNA and protein expressions. (A) The plasma levels of nitrite/nitrate were measured in rats as described in materials and methods. (B) RNA was extracted from spinal cord tissue homogenates and iNOS mRNA levels measured using primers as indicated in materials and methods. The iNOS mRNA expression levels were normalized with endogenous control (GAPDH) and expressed as relative to control. (C) The iNOS protein levels were determined in spinal cord tissue homogenates by western blot as described in materials and methods. β-actin used as a loading control. Protein signals were quantified by ChemiDoc and normalized to β-actin signals, are presented as relative expression. Con: Control group; Resv: resveratrol control group; Sham: Sham group; IRI: ischemia–reperfusion injury group; IRI + Resv: resveratrol treated ischemia–reperfusion injury group. Results are expressed as mean ± SD (n = 7). ⁎p < 0.001 compared with IRI group.
Figure 2Effect of resveratrol on p38MPAK pathway. (A) The protein expressions of phospho-p38 MPAK, total MAPK and β-actin were determined in spinal cord tissue homogenates by western blot as described in materials and methods. β-actin used as a loading control. (B) Protein signals were quantified by ChemiDoc and normalized to β-actin signals, are presented as relative expression. Con: Control group; Resv: resveratrol control group; Sham: Sham group; IRI: ischemia–reperfusion injury group; IRI + Resv: resveratrol treated ischemia–reperfusion injury group. Results are expressed as mean ± SD (n = 7). ⁎p < 0.001 compared with IRI group.
Figure 3Effect of resveratrol on lipid peroxidation (MDA) and oxidation (AOPP) products. (A) Malondialdehyde (MDA) and (B) advanced oxidation products (AOPP) were measured in spinal cord tissue homogenates and expressed as nmol/g protein. Con: Control group; Resv: resveratrol control group; Sham: Sham group; IRI: ischemia–reperfusion injury group; IRI + Resv: resveratrol treated ischemia–reperfusion injury group. Results are expressed as mean ± SD (n = 7). ⁎p < 0.001 compared with IRI group.
Figure 4Effect of resveratrol on the level of reduced glutathione (GSH). Reduced glutathione levels were measured in spinal cord tissue homogenates and expressed as mg/g protein. Con: Control group; Resv: resveratrol control group; Sham: Sham group; IRI: ischemia–reperfusion injury group; IRI + Resv: resveratrol treated ischemia–reperfusion injury group. Results are expressed as mean ± SD (n = 7). ⁎p < 0.001 compared with IRI group.
Figure 5Effect of resveratrol on the activities of SOD and CAT. SOD and CAT enzyme activities were measured in spinal cord tissue homogenates and expressed as unit/mg protein. Con: Control group; Resv: resveratrol control group; Sham: Sham group; IRI: ischemia–reperfusion injury group; IRI + Resv: resveratrol treated ischemia–reperfusion injury group. Results are expressed as mean ± SD (n = 7). ⁎p < 0.001 compared with IRI group.